MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6699
-0.0340
-4.83%
Closed 16:00 04/01 EDT
OPEN
0.7200
PREV CLOSE
0.7039
HIGH
0.7200
LOW
0.6600
VOLUME
155.68K
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
0.6460
MARKET CAP
24.22M
P/E (TTM)
-0.6833
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRIS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.

EPS

CRIS News

More
  • Edited Transcript of CRIS earnings conference call or presentation 19-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 6d ago
  • Curis reports Q4 results
  • seekingalpha · 03/20 01:04
  • Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/19 23:33
  • Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
  • PR Newswire · 03/19 21:01

Industry

Biotechnology & Medical Research
-4.51%
Pharmaceuticals & Medical Research
-2.97%

Hot Stocks

Symbol
Price
%Change

About CRIS

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
More

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.